No Data
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Earnings Preview: LIVZON PHARMA to Report Financial Results on April 23
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Hong Kong stock morning report | John Lee Ka-chiu engaged in in-depth exchanges with representatives of the "Hangzhou Six Little Dragons" companies. Trump is considering exempting Auto Manufacturers from some tariffs.
① John Lee Ka-chiu had in-depth discussions with representatives from the 'Six Little Dragons of Hangzhou.' ② The Inner Mongolia Ministry of Industry and Information Technology reported that the computing power scale of Inner Mongolia has reached around 0.12 million P, ranking first in the country. ③ USA President Trump is considering exempting Auto Manufacturers from certain tariffs. ④ NIO's Li Bin predicts that China's share of the Global auto industry will exceed 40%.
Livzon Pharmaceutical Group Inc.: 2025 First Quarter Report
LIVZON PHARMA (01513.HK) reported a Net income of 0.637 billion yuan in the first quarter, representing a year-on-year growth of 4.75%.
Glory Exchange April 23丨LIVZON PHARMA (01513.HK) announced that in the first quarter of 2025, the company's revenue was 3.18 billion yuan, a year-on-year decrease of 1.92%; net income attributable to shareholders of the listed company was 0.637 billion yuan, an increase of 4.75% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.619 billion yuan, an increase of 4.82% year-on-year; EPS was 0.71 yuan/share.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet